Quick Answer
ImageneBio, Inc. reported Cash And Cash Equivalents At Carrying Value of $94.53 million for the year ending 2025.
- ImageneBio, Inc. showed an increase of +680.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from ImageneBio, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $72.11 million | Q2 2020: $63.53 million | Q3 2020: $55.86 million | Q1 2021: $281.01 million | Q2 2021: $264.00 million | Q3 2021: $245.90 million | Q1 2022: $46.88 million | Q2 2022: $48.49 million | Q3 2022: $67.07 million | Q1 2023: $29.33 million | Q2 2023: $70.87 million | Q3 2023: $121.28 million | Q1 2024: $52.85 million | Q2 2024: $44.27 million | Q3 2024: $45.19 million | Q1 2025: $36.76 million | Q2 2025: $58.29 million | Q3 2025: $103.16 million.
- Over the full 6 years of available data (2020 to 2025), ImageneBio, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 41.8%.
- Historical annual values: Fiscal year 2025: $94.53 million | Fiscal year 2024: $12.12 million | Fiscal year 2023: $119.89 million | Fiscal year 2022: $59.92 million | Fiscal year 2021: $232.22 million | Fiscal year 2020: $162.49 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: